Amarin (AMRN) Q1 2026 earnings review
Partner Strategy Stabilizes Top-Line, But Crushes Gross Margins
Amarin is successfully executing its transition to a capital-light, partner-driven model. Total Revenue grew 7% YoY to $45.1M, breaking a multi-quarter streak of structural declines. Aggressive cost cuts—with SG&A down 42% YoY—narrowed the operating loss to $11.3M and kept the company cash flow positive for the second consecutive quarter. However, the shift from direct sales to partner supply in Europe drastically altered the margin profile. Gross Margin collapsed to 39.4% from 59.8% a year ago. While the U.S. 'cash cow' remains stable against generic competition, Amarin's future valuation hinges on whether European volume gains via Recordati can offset the structurally lower margins of a licensing model.
🐂 Bull Case
The $70M restructuring program initiated in mid-2025 is yielding tangible results. SG&A has been cut nearly in half YoY, aligning expenses with the new partnership-dominant business model and securing positive cash flow generation.
Five years post-generic entry, U.S. VASCEPA sales stabilized at $35.6M (flat YoY). The company has successfully defended its market share and maintained exclusive payer contracts, providing a reliable cash engine to fund global efforts.
🐻 Bear Case
COGS surged 62% YoY despite only a 7% increase in revenue. The transition to a partner model means Amarin is recognizing lower-margin supply sales to Recordati and ROW partners, permanently altering the company's gross profitability profile.
While Net Loss improved YoY (-$10.5M vs -$15.7M), it widened significantly on a sequential basis compared to Q4 2025 (-$1.2M). The path to GAAP profitability remains elusive without milestone payments.
⚖️ Verdict: ⚪
Neutral. Management has executed the cost-cutting playbook perfectly, saving the balance sheet and generating cash. However, the 20-point drop in gross margin reveals the harsh reality of transitioning to a royalty and supply-based partnership model. Volume growth must accelerate dramatically to compensate for the lower margins.
Key Themes
Gross Margin Collapse as Partner Model Takes Hold
A critical red flag emerged in the profitability metrics. Gross margin plummeted from 59.8% in 25Q1 to 39.4% in 26Q1. COGS increased by $10.5M (+62% YoY) due to increased shipments to the exclusive U.S. PBM and, more importantly, low-margin supply shipments to Recordati and ROW partners. This confirms that while the partner model saves operating expenses, it structurally caps gross profitability.
European Revenue Contradicts Positive Narrative
Management touted 'encouraging' initial results and higher European product revenue sequentially (vs 25Q4). However, digging into the data reveals European revenue actually declined 9% YoY ($4.9M vs $5.4M). This deceleration reflects the structural pricing difference between direct in-market sales (prior model) and selling supply to Recordati at a transfer price (current model).
Aggressive OpEx Restructuring Achieved
The company's June 2025 Global Restructuring plan is fully visible in the income statement. SG&A expenses fell by 42% YoY to $21.1M. Operating Loss narrowed by 32% to $11.3M despite the gross margin pressures. This operational discipline is the sole reason the company is now generating positive cash flow.
U.S. Franchise Stability
Despite intense generic competition for five years, U.S. product revenue was essentially flat YoY at $35.6M. Regaining exclusive status with a large national PBM in Q3 2025 provided a necessary volume offset to continuous net pricing pressure. The U.S. business remains the foundational cash engine for the company.
Macro Tailwind: ACC/AHA Dyslipidemia Guidelines Update
The March 2026 update to the ACC/AHA Multisociety Dyslipidemia Guidelines acts as a significant macro catalyst. The guidelines emphasize comprehensive cardiovascular risk management beyond LDL cholesterol lowering. This external validation shifts the standard of care toward early, lifelong prevention for patients with elevated triglycerides, directly supporting the clinical narrative for Icosapent Ethyl (VASCEPA/VAZKEPA) globally.
Strategic Limbo and Barclays Engagement
Management continues to highlight that they are working closely with Barclays to explore 'additional potential pathways to further enhance shareholder value.' While framed as a positive, the ongoing presence of an exclusive financial advisor suggests that the current standalone, partner-heavy model may simply be an interim step toward a sale or merger, adding strategic uncertainty.
Other KPIs
Accelerating. Up sequentially from $302.6M at the end of 2025. Generating positive cash flow for a second consecutive quarter highlights the effectiveness of the cost-cutting initiatives. The balance sheet remains pristine with zero debt, providing ample runway.
Accelerating YoY from $0 in 25Q1, but still displaying the inherent lumpiness of a partner model compared to the $11.9M peak seen in prior stocking quarters. Execution in these nascent markets (China, Australia, MENA) remains difficult to forecast.
Accelerating. Up 84% from $1.0M in 25Q1. While still a small absolute number, this is the highest quality revenue line on the income statement as it carries near 100% margin. This metric will be the ultimate barometer for Recordati's success in Europe.
Guidance
Stable. The company reiterated its expectation to remain cash flow positive for the full year, a critical milestone achieved by aligning the operating expenses with the realities of the genericized U.S. market and the royalty-based European market.
Stable. The company confirmed it remains on track to realize the previously guided $70M in annualized cost savings. Crucially, they noted that nearly all of the associated restructuring charges ($39.6M incurred to date) are complete, removing a major headwind from the Q2-Q4 cash flow profile.
Key Questions
Normalized Gross Margin Run-Rate
With gross margin compressing to 39% due to the partner supply mix, where does management see the consolidated gross margin settling once Recordati is fully ramped across all 10 target countries?
Barclays Strategic Review Status
The company has been exploring strategic pathways with Barclays since mid-2025. What is the timeline for concluding this review, and are whole-company sale options being prioritized over regional licensing?
Recordati Milestone Triggers
The licensing and royalty revenue grew nicely YoY, but absolute dollars remain low. When does management realistically expect Recordati to cross the $100M sales threshold required to trigger the first major commercial milestone payment?
U.S. Pricing vs Volume
U.S. revenue was flat YoY. Given the typical Q1 payer dynamics and deductible resets, how much of this stability was driven by underlying prescription volume growth versus adjustments in net pricing?